328 related articles for article (PubMed ID: 28912274)
1. Structure, mechanism, and regulation of polycomb-repressive complex 2.
Moritz LE; Trievel RC
J Biol Chem; 2018 Sep; 293(36):13805-13814. PubMed ID: 28912274
[TBL] [Abstract][Full Text] [Related]
2. Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment.
Cook N; Chen J; Zhou J; Wu D
Curr Top Med Chem; 2021; 21(31):2771-2777. PubMed ID: 34544341
[TBL] [Abstract][Full Text] [Related]
3. Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance.
Brooun A; Gajiwala KS; Deng YL; Liu W; Bolaños B; Bingham P; He YA; Diehl W; Grable N; Kung PP; Sutton S; Maegley KA; Yu X; Stewart AE
Nat Commun; 2016 Apr; 7():11384. PubMed ID: 27122193
[TBL] [Abstract][Full Text] [Related]
4. A Structural Perspective on Gene Repression by Polycomb Repressive Complex 2.
Liu X
Subcell Biochem; 2021; 96():519-562. PubMed ID: 33252743
[TBL] [Abstract][Full Text] [Related]
5. Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain.
Antonysamy S; Condon B; Druzina Z; Bonanno JB; Gheyi T; Zhang F; MacEwan I; Zhang A; Ashok S; Rodgers L; Russell M; Gately Luz J
PLoS One; 2013; 8(12):e84147. PubMed ID: 24367637
[TBL] [Abstract][Full Text] [Related]
6. Inner workings and regulatory inputs that control Polycomb repressive complex 2.
O'Meara MM; Simon JA
Chromosoma; 2012 Jun; 121(3):221-34. PubMed ID: 22349693
[TBL] [Abstract][Full Text] [Related]
7. Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer.
Martin MC; Zeng G; Yu J; Schiltz GE
J Med Chem; 2020 Dec; 63(24):15344-15370. PubMed ID: 33283516
[TBL] [Abstract][Full Text] [Related]
8. Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2.
Justin N; Zhang Y; Tarricone C; Martin SR; Chen S; Underwood E; De Marco V; Haire LF; Walker PA; Reinberg D; Wilson JR; Gamblin SJ
Nat Commun; 2016 Apr; 7():11316. PubMed ID: 27121947
[TBL] [Abstract][Full Text] [Related]
9. Structure of the PRC2 complex and application to drug discovery.
Shi Y; Wang XX; Zhuang YW; Jiang Y; Melcher K; Xu HE
Acta Pharmacol Sin; 2017 Jul; 38(7):963-976. PubMed ID: 28414199
[TBL] [Abstract][Full Text] [Related]
10. Convergent evolution of chromatin modification by structurally distinct enzymes: comparative enzymology of histone H3 Lys²⁷ methylation by human polycomb repressive complex 2 and vSET.
Swalm BM; Hallenbeck KK; Majer CR; Jin L; Scott MP; Moyer MP; Copeland RA; Wigle TJ
Biochem J; 2013 Jul; 453(2):241-7. PubMed ID: 23679895
[TBL] [Abstract][Full Text] [Related]
11. Role of the polycomb protein EED in the propagation of repressive histone marks.
Margueron R; Justin N; Ohno K; Sharpe ML; Son J; Drury WJ; Voigt P; Martin SR; Taylor WR; De Marco V; Pirrotta V; Reinberg D; Gamblin SJ
Nature; 2009 Oct; 461(7265):762-7. PubMed ID: 19767730
[TBL] [Abstract][Full Text] [Related]
12. Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations.
Wu H; Zeng H; Dong A; Li F; He H; Senisterra G; Seitova A; Duan S; Brown PJ; Vedadi M; Arrowsmith CH; Schapira M
PLoS One; 2013; 8(12):e83737. PubMed ID: 24367611
[TBL] [Abstract][Full Text] [Related]
13. Polycomb repressive complex 2 inhibitors: emerging epigenetic modulators.
Danishuddin ; Subbarao N; Faheem M; Khan SN
Drug Discov Today; 2019 Jan; 24(1):179-188. PubMed ID: 30031878
[TBL] [Abstract][Full Text] [Related]
14. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2.
Jiao L; Liu X
Science; 2015 Oct; 350(6258):aac4383. PubMed ID: 26472914
[TBL] [Abstract][Full Text] [Related]
16. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
17. Long residence time inhibition of EZH2 in activated polycomb repressive complex 2.
Van Aller GS; Pappalardi MB; Ott HM; Diaz E; Brandt M; Schwartz BJ; Miller WH; Dhanak D; McCabe MT; Verma SK; Creasy CL; Tummino PJ; Kruger RG
ACS Chem Biol; 2014 Mar; 9(3):622-9. PubMed ID: 24304166
[TBL] [Abstract][Full Text] [Related]
18. Polycomb repressive complex 2 in an autoinhibited state.
Bratkowski M; Yang X; Liu X
J Biol Chem; 2017 Aug; 292(32):13323-13332. PubMed ID: 28607149
[TBL] [Abstract][Full Text] [Related]
19. Structure-Guided Design of EED Binders Allosterically Inhibiting the Epigenetic Polycomb Repressive Complex 2 (PRC2) Methyltransferase.
Lingel A; Sendzik M; Huang Y; Shultz MD; Cantwell J; Dillon MP; Fu X; Fuller J; Gabriel T; Gu J; Jiang X; Li L; Liang F; McKenna M; Qi W; Rao W; Sheng X; Shu W; Sutton J; Taft B; Wang L; Zeng J; Zhang H; Zhang M; Zhao K; Lindvall M; Bussiere DE
J Med Chem; 2017 Jan; 60(1):415-427. PubMed ID: 27992714
[TBL] [Abstract][Full Text] [Related]
20. EZH2 as a potential target in cancer therapy.
McCabe MT; Creasy CL
Epigenomics; 2014 Jun; 6(3):341-51. PubMed ID: 25111487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
